The adjustment in price target by RBC Capital, while maintaining an Outperform rating, suggests a slight recalibration of expectations rather than a fundamental shift in the company's outlook. The reduction is minimal, indicating that the overall positive stance on Biohaven's potential remains intact. This could lead to a neutral short-term impact on the stock as the market digests the minor adjustment in valuation expectations.